We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Synergy Pharmaceuticals - Unit | NASDAQ:SGYPU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.7547 | 9.92 | 11.44 | 0 | 01:00:00 |
The poster presentation is Sunday, May 20, 8:00 am to 5:00 pm at the San Diego Convention Center.
Poster Su1189: Identification of Cardinal Symptoms in Patients with Chronic Idiopathic Constipation (CIC). Alan Joslyn1, Laura Barrow1, Gary S. Jacob1 and Jean Paty2
1Synergy Pharmaceuticals, 420 Lexington Ave., Suite 1609, New York, NY, USA; 2PRO Consulting, 2100 Wharton Street, Suite 505, Pittsburgh, PA 15203
About Synergy Pharmaceuticals, Inc.
Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in CIC patients. In October, 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide to treat chronic idiopathic constipation. Plecanatide is also being developed to treat IBS-C, with the first trial in IBS-C patients planned for 2H2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. More information is available at http://www.synergypharma.com.
CONTACT: Investor Contact Information: Danielle Spangler The Trout Group synergy@troutgroup.com (646) 378-2924
1 Year Synergy Pharmaceuticals - Unit Chart |
1 Month Synergy Pharmaceuticals - Unit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions